Physiomics signs up 'major' pharmaceutical client

Writer, Stock Market Wire
Friday, February 9, 2018 - 07:24

Physiomics said it had been awarded a contract by a 'global top-10' pharmaceutical client, without being more specific.

The project had a value of £70k and was expected to be completed during the company's current financial year.

Chief executive Jim Millen said: 'We believe that the signing of agreements with three major pharmaceutical clients within the space of three months is a real sign of the confidence in our technology that is starting to build within the industry.'

'Our aim now will be to develop longer-term relationships with these major companies and to secure further pre-clinical and clinical projects.'

Related content

Physiomics extends collaboration agreement with Merck

Physiomics said it had extended a collaboration pact with Merck for the next calendar year related to cancer treatments.

Physiomics and Merck had entered into...

Mon, 17/12/2018 - 08:14

Physiomics losses narrow after contract wins

Cancer treatment evaluation group Physiomics said its annual losses narrowed after it almost doubled its revenue.

Pre-tax losses for the year through June amounted to...

Mon, 08/10/2018 - 08:24

Physiomics says it is anticipated to beat market expectations

Physiomics confirmed that based on its current unaudited accounts at 20 June, it is trading ahead of market expectations for its full financial year ending...

Thu, 21/06/2018 - 07:38

Physiomics wins UK government grant for cancer treatment study

Physiomics, a provider of technology-based solutions to predict the effects of cancer treatment regimens, said it had been awarded a grant by the UK government....

Wed, 14/03/2018 - 09:29

Physiomics completes UK grant project for cancer treatment

Physiomics said it had successfully completed a UK grant project related to improving cancer treatments that received £131k of state funding.

The project, dubbed 'Decision...

Mon, 12/03/2018 - 09:31